StemBioSys, a San Antonio company that manufactures and develops stem cell technologies in the regenerative medicine field, has landed $2,377,802.
It still seeks $5,622,198, according to the regulatory filing. The company is in a quiet period of funding right now, Chairman of the Board Dr. Steve Davis said.
That period should end Aug. 5, so be sure to check back here for more news as the story develops.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
According to the company website, the “centerpiece” of its expansion is the “XC-marrow ECM™, a patented “extracellular matrix” laid down by human bone marrow mesenchymal stem cells (MSCs)–a 3D microenvironment that allows stem cells to replicate more rapidly and with greater preservation of stem cell phenotypes (“stemness”) than traditional tissue culture plastic. It allows SBS to grow stem cells from sources such as adipose tissue, bone marrow and umbilical cord blood, opening up potential for research, pharmaceutical and novel clinical uses.”
Officers include Davis, Chief Scientific Officer Dr. Xiao-Dong Chen, Edward “Sy” Griffey and CEO Peter Savas.